Network analysis of changes in post-migration stressors during treatment for refugees with PTSD.

Eur J PsychotraumatolJan 26, 2026 (epub)
Clinical ResearchPsychiatryOpen access

Maja Bruhn, Henriette Laugesen Attardo, Tobias Spiller et al.

✦ AI-curated · Sources linked

In 30 seconds

This study examined how post-migration stressors changed during multidisciplinary mental health treatment among refugees with PTSD at a specialised clinic in Denmark. Although conducted within a randomised controlled trial, the reported analysis compared pre- and post-treatment stressor networks. Overall checklist scores did not change, but global network connectivity increased significantly (p = .004), indicating stronger interrelations among stressors after treatment. Financial and housing-related stress decreased, while concern about returning to the country of origin in an emergency increased. The findings describe changes in stressor patterns, not the effect of a specific treatment on those patterns.

Key findings

  • Global network connectivity increased from pre- to post-treatment (p = .004), despite no change in the overall post-migration difficulties score.
  • Financial stress decreased (p = .006), as did housing-related stress (p = .028).
  • Concern about returning to the country of origin in an emergency increased (p = .028).

Why it matters

A stable overall burden can conceal changes in how post-migration difficulties relate to one another. The increased interconnection observed here highlights that financial, housing, and other stressors may not operate independently during treatment. Considering these difficulties in their social and structural context may help clinicians and services understand challenges that mental health care alone may not address.

What to keep in mind

The analysis reports pre- and post-treatment network comparisons and does not establish that treatment caused the observed changes. The abstract provides no sample size or follow-up beyond the post-treatment assessment.

Source

Published in Eur J Psychotraumatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.